🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07597772
Recruiting Phase EARLY_PHASE1

Preliminary Trial of SNA014 for Pancreatic Cancer

NCT07597772 · tracked via the Priya Life Science China tracker
Sponsor
SmartNuclide Biopharma
Phase
Phase EARLY_PHASE1
Started
2025-10-01
Last updated
2026-05-19

Condition(s) studied

Pancreatic Cancer

Investigational drug(s) / intervention(s)

68Ga-NODAGA-SNA006 →

68Ga-NODAGA-SNA006: Administration

Study summary

68Ga labeled Claudin 18.2 contrast agent combined with PET/CT for pancreatic cancer

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: 1. Aged between 18 and 75 years (inclusive); 2. Possessing legal capacity, voluntarily participating in this clinical trial, and having signed the informed consent form (ICF); 3. Patients with a confirmed diagnosis of pancreatic cancer whose tumours are suitable for Claudin-18.2 testing; 4. Results of gastroscopy, CT, MRI or PET-CT scans performed within the past month (if available); 5. Pathology test results from within the past year; Exclusion Criteria: 1. Patients with other clearly diagnosed malignant tumours; 2. Patients with uncontrolled severe infections, or those with other serious comorbidities; 3. Patients with a life expectancy of ≤3 months; 4. Pregnant or breastfeeding patients, and patients of childbearing potential who refuse to use appropriate contraception during the trial; 5. Patients deemed unsuitable for participation in this study by the investigator.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Tianjin Medical University Cancer Institute and Hospital Tianjin Tianjin Municipality Recruiting

More SmartNuclide Biopharma trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07597772 on ClinicalTrials.gov ↗ ← All trials in China